Brexit Won't Impair Pharmacovigilence 'Fundamentals' – DIA Panel
Executive Summary
MHRA pharmacovigilance leader says global safety efforts will not lose UK expertise.
You may also be interested in...
The Post-Shutdown Quality Lowdown
Quality oversight activity began ramping back up after the partial US government shutdown, even as EU oversight activities entered into a Brexit-related slowdown.
How The UK Regulatory System Would Work In A No-Deal Brexit – Part 2
In this second article on the regulations published by the government on how the UK would regulate medicines in a “no-deal” Brexit scenario, we look at what is being proposed for areas such as pediatric investigation plans, orphan medicines, pharmacovigilance, parallel trade, generics approvals, and good manufacturing and distribution practices.
How The UK Regulatory System Would Work In A No-Deal Brexit – Part 1
Regulations that would allow the UK MHRA to work as a standalone regulator in the event of a no-deal Brexit have been laid before parliament. They cover a host of areas including new drug approval procedures, conversion of existing EU marketing authorizations into UK ones, pediatric and orphan exclusivities, imported medicines, and regulatory fees.